Product Description
Recently, a synthetic DNA vaccine, INO-4201, was tested in humans and showed good immunogenicity and an enhanced safety profile. For Ebola Virus disease (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04906629)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Inovio
Company Location: SAN DIEGO CA 92121
Company CEO: Jacqueline E. Shea
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hemorrhagic Fever, Ebola
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04906629 |
Boost-EBOV | P1 |
Completed |
Hemorrhagic Fever, Ebola |
2022-01-05 |
50% |
2022-05-27 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/09/2025 |
News Article |
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments |
|
07/01/2024 |
News Article |
INOVIO Added to Russell 2000® Index Effective July 1, 2024 |
|
04/17/2023 |
News Article |
Data from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) presented at ECCMID 2023 |
|
04/12/2023 |
News Article |
INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023 |